ArticleFrontiers in oncology2026
The impact of liposomal bupivacaine erector spinae plane block on postoperative analgesia and early functional recovery in patients undergoing thoracoscopic lung cancer surgery.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Liposomal Bupivacaine in Perioperative Analgesia: A Comprehensive Review of Clinical Efficacy, Safety, and Economic Context.Current pain and headache reports · 2026Review
- Liposomal bupivacaine in thoracic surgery: a comprehensive review of current evidence and clinical implications.Frontiers in medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: This study aimed to evaluate the impact of liposomal bupivacaine erector spinae plane block (ESPB) on postoperative analgesia and early functional recovery in patients undergoing thoracoscopic lung cancer surgery. Methods: A retrospective analysis was conducted on 246 patients who underwent video-assisted thoracoscopic surgery (VATS) for lung cancer from January 2021 to December 2023. Patients were divided into two groups based on the type of local anesthetic used for ESPB: bupivacaine (n=115) and liposomal bupivacaine (n=131). Postoperative pain levels, early functional recovery, opioid consumption, pulmonary function indices, perioperative adverse events, and other postoperative-related outcomes were assessed. Results: Patients receiving liposomal bupivacaine reported lower pain scores at rest during the first 48 hours postoperatively compared to those receiving conventional bupivacaine. The liposomal bupivacaine group also demonstrated higher Quality of Recovery-15 (QoR-15) scores, reduced postoperative sufentanil consumption, and improved pulmonary function indices (FEV1 and FVC) throughout the observation period. Additionally, the time to first ambulation was shorter, and the time to the first request for analgesia was longer in the liposomal bupivacaine group (all P<0.05). No significant differences were observed in perioperative adverse events between the groups (P>0.05). Conclusions: Liposomal bupivacaine ESPB is associated with improved postoperative analgesia and earlier functional recovery in patients undergoing VATS for lung cancer. These observed benefits may be attributed to the prolonged release profile of bupivacaine, which correlates with sustained pain relief and reduced opioid requirements. This technique holds promise for optimizing postoperative care and enhancing patient recovery following thoracic surgery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.